Related Experiment Videos
Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug
1Rambam Medical Center, The Bruce Rappaport Faculty of Medicine, Technion, and the Rappaport Family Institute for Research in the Medical Sciences, Haifa, Israel.
Insights
Fluvastatin therapy significantly reduces platelet aggregation in patients with high cholesterol. This cholesterol-lowering drug has a dual effect, impacting both platelet cholesterol content and directly binding to platelets.
Area of Science:
- Cardiovascular Pharmacology
- Atherosclerosis Research
- Platelet Biology
Background:
- High plasma cholesterol and increased platelet activity are key risk factors for atherosclerosis.
- Lovastatin (lipophilic) inhibits platelet aggregation, while pravastatin (hydrophilic) does not.
Purpose of the Study:
- To investigate the effect of fluvastatin, a drug with both lipophilic and hydrophilic properties, on platelet aggregation.
- To compare fluvastatin's direct effects on platelets with other statins.
Main Methods:
- Administered fluvastatin (40 mg daily) to 25 hypercholesterolemic patients for up to 24 weeks.
- Monitored plasma lipids, platelet aggregation, and platelet fluidity.
- Compared fluvastatin's direct effect on platelets with lovastatin and pravastatin in vitro.
Main Results:
- Fluvastatin therapy reduced total cholesterol by 23% and LDL-cholesterol by 29% within 4 weeks.
- Platelet aggregation decreased by 10% after 4 weeks and up to 15% with continued therapy.
- Fluvastatin and lovastatin dose-dependently inhibited platelet aggregation in vitro, unlike pravastatin, suggesting shared binding sites.
Conclusions:
- Fluvastatin reduces platelet aggregation through both its cholesterol-lowering effects and direct binding to platelets.
- The antiatherogenic potential of fluvastatin may stem from its cholesterol-lowering ability and its inhibitory effect on platelet activation.
Aims:
High plasma cholesterol concentration and increased platelet activity are two major risk factors for atherosclerosis. Lovastatin, the lipophilic drug was shown to inhibit platelet aggregation whereas pravastatin, the hydrophilic drug had no such effect. Analysis of the effect of fluvastatin which is both a lipophilic and hydrophilic drug, on platelet aggregation was the goal of the present study.
Methods:
Fluvastatin 40 mg daily was administered to 25 patients with hypercholesterolaemia for up to 24 weeks. Normal subjects acted as controls. The influence of fluvastatin on plasma lipids and on platelet aggregation and fluidity was studied. The direct effect of fluvastatin on platelets was compared with that of other statins.
Results:
Fluvastatin therapy (40 mg day (-1) for a period of 4 weeks) in hypercholesterolaemic patients resulted in a 23% and 29% reduction in plasma levels of total cholesterol and LDL-cholesterol respectively. Platelet cholesterol/phospholipids molar ratio was reduced by 26% and platelet aggregation was significantly (P<0.02) reduced by 10% after 4 weeks of fluvastatin treatment. On continuing fluvastatin therapy for additional 20 weeks, no further decrement in plasma LDL cholesterol levels or in platelet cholesterol/phospholipid ratio were noted. However, platelet aggregation was further significantly (P<0.01) reduced by up to 15%. Incubation of platelets with increasing concentrations of fluvastatin or lovastatin, demonstrated a dose-dependent reduction in platelet aggregation, whereas pravastatin showed no effect. This inhibitory effect of fluvastatin or lovastatin on platelet aggregation (up to 34% or 22% respectively at a concentration of 1 microg statin ml (-1) was found both in platelet rich plasma and in washed platelet suspensions. Fluvastatin and lovastatin (but not pravastatin), seem to share similar platelet binding sites, as non labelled fluvastatin or lovastatin were able to displace [3H]-labeled-fluvastatin from its binding sites on platelets.
Conclusions:
Fluvastatin therapy reduces platelet aggregation via a dual effect which involves its in vivo hypocholesterolaemic action on platelet cholesterol content, and also a direct effect of the drug binding to the platelets. The antiatherogenicity of fluvastatin may be related, in addition to its plasma cholesterol lowering ability, to its inhibitory effect on platelet activation.